Referências
Principais artigos
National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association, and the Infectious Disease Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. 2025 [internet publication].Texto completo
Horberg M, Thompson M, Agwu A, et al. Primary care guidance for providers of care for persons with human immunodeficiency virus: 2024 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2024 Oct 12:ciae479.Texto completo Resumo
The Mind Exchange Working Group. Assessment, diagnosis and treatment of human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND): a consensus report of the Mind Exchange Program. Clin Infect Dis. 2013 Apr;56(7):1004-17. Resumo
European AIDS Clinical Society. Guidelines: version 12.1 Nov 2024 [internet publication].Texto completo
Artigos de referência
1. Pandya R, Krentz HB, Gill MJ, et al. HIV-related neurological syndromes reduce health-related quality of life. Can J Neurol Sci. 2005 May;32(2):201-4. Resumo
2. Banerjee N, McIntosh RC, Ironson G. Impaired neurocognitive performance and mortality in HIV: assessing the prognostic value of the HIV-dementia scale. AIDS Behav. 2019 Dec;23(12):3482-92.Texto completo Resumo
3. Levine AJ, Hinkin CH, Ando K, et al. An exploratory study of long-term neurocognitive outcomes following recovery from opportunistic brain infections in HIV+ adults. J Clin Exp Neuropsychol. 2008 Oct;30(7):836-43. Resumo
4. Diaz MM, McCutchan JA, Crescini M, et al. Longitudinal study of cognitive function in people with HIV and toxoplasmic encephalitis or latent toxoplasma infection. AIDS. 2024 Dec 1;38(15):2021-9. Resumo
5. Paternò Raddusa MS, Marino A, Celesia BM, et al. Atherosclerosis and cardiovascular complications in people living with HIV: a focused review. Infect Dis Rep. 2024 Sep 1;16(5):846-63.Texto completo Resumo
6. Chow FC, Regan S, Zanni MV, et al. Elevated ischemic stroke risk among women living with HIV infection. AIDS. 2018 Jan 2;32(1):59-67.Texto completo Resumo
7. Lima VD, Geller J, Bangsberg DR, et al. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS. 2007 May 31;21(9):1175-83. Resumo
8. Leserman J. HIV disease progression: depression, stress, and possible mechanisms. Biol Psychiatry. 2003 Aug 1;54(3):295-306. Resumo
9. Pence BW, Miller WC, Gaynes BN, et al. Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):159-66. Resumo
10. Elliott AJ, Russo J, Roy-Byrne PP. The effect of changes in depression on health related quality of life (HRQoL) in HIV infection. Gen Hosp Psychiatry. 2002 Jan-Feb;24(1):43-7. Resumo
11. Claypoole KH, Elliott AJ, Uldall KK, et al. Cognitive functions and complaints in HIV-1 individuals treated for depression. Appl Neuropsychol. 1998;5(2):74-84. Resumo
12. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010 Dec 7;75(23):2087-96.Texto completo Resumo
13. Gray F, Chrétien F, Vallat-Decouvelaere AV, et al. The changing pattern of HIV neuropathology in the HAART era. J Neuropathol Exp Neurol. 2003 May;62(5):429-40. Resumo
14. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007 Oct 30;69(18):1789-99. Resumo
15. Parsons TD, Braaten AJ, Hall CD, et al. Better quality of life with neuropsychological improvement on HAART. Health Qual Life Outcomes. 2006 Feb 24;4:11.Texto completo Resumo
16. Gibbie T, Mijch A, Ellen S, et al. Depression and neurocognitive performance in individuals with HIV/AIDS: 2-year follow-up. HIV Med. 2006 Mar;7(2):112-21. Resumo
17. Larussa D, Lorenzini P, Cingolani A, et al. Highly active antiretroviral therapy reduces the age-associated risk of dementia in a cohort of older HIV-1-infected patients. AIDS Res Hum Retroviruses. 2006 May;22(5):386-92. Resumo
18. Joska JA, Gouse H, Paul RH, et al. Does highly active antiretroviral therapy improve neurocognitive function? A systematic review. J Neurovirol. 2010 Mar;16(2):101-14. Resumo
19. Wilkie FL, Goodkin K, Eisdorfer C, et al. Mild cognitive impairment and risk of mortality in HIV-1 infection. J Neuropsychiatry Clin Neurosci. 1998 Spring;10(2):125-32. Resumo
20. Sakai M, Higashi M, Fujiwara T, et al. MRI imaging features of HIV-related central nervous system diseases: diagnosis by pattern recognition in daily practice. Jpn J Radiol. 2021 Nov;39(11):1023-38.Texto completo Resumo
21. Elendu C, Aguocha CM, Okeke CV, et al. HIV-related neurocognitive disorders: diagnosis, treatment, and mental health implications: a review. Medicine (Baltimore). 2023 Oct 27;102(43):e35652.Texto completo Resumo
22. National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association, and the Infectious Disease Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. 2025 [internet publication].Texto completo
23. Horberg M, Thompson M, Agwu A, et al. Primary care guidance for providers of care for persons with human immunodeficiency virus: 2024 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2024 Oct 12:ciae479.Texto completo Resumo
24. Blanch J, Martínez E, Rousaud A, et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr. 2001 Aug 1;27(4):336-43. Resumo
25. Hawkins T, Geist C, Young B, et al. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin Trials. 2005 Jul-Aug;6(4):187-96. Resumo
26. Gazzard B, Balkin A, Hill A. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review. AIDS Rev. 2010 Apr-Jun;12(2):67-75. Resumo
27. Cavalcante GI, Capistrano VL, Cavalcante FS, et al. Implications of efavirenz for neuropsychiatry: a review. Int J Neurosci. 2010 Dec;120(12):739-45. Resumo
28. Decloedt EH, Maartens G. Neuronal toxicity of efavirenz: a systematic review. Expert Opin Drug Saf. 2013 Nov;12(6):841-6. Resumo
29. Cohen CJ, Andrade-Villanueva J, Clotet B, et al; THRIVE Study Group. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011 Jul 16;378(9787):229-37. Resumo
30. Katlama C, Haubrich R, Lalezari J, et al; DUET-1, DUET-2 Study Groups. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS. 2009 Nov 13;23(17):2289-300. Resumo
31. Madeddu G, Menzaghi B, Ricci E, et al. Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study. AIDS. 2012 Nov 28;26(18):2412-5. Resumo
32. Harris M, Larsen G, Montaner JG. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008 Sep 12;22(14):1890-2. Resumo
33. Gray J, Young B. Acute onset insomnia associated with the initiation of raltegravir: a report of two cases and literature review. AIDS Patient Care STDs. 2009 Sep;23(9):689-90. Resumo
34. Walmsley SL, Antela A, Clumeck N, et al; SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013 Nov 7;369(19):1807-18.Texto completo Resumo
35. Lepik KJ, Yip B, Ulloa AC, et al. Adverse drug reactions to integrase strand transfer inhibitors. AIDS. 2018 Apr 24;32(7):903-12. Resumo
36. van den Berk G, Oryszczyn J, Blok W, et al. Unexpectedly high rate of intolerance for dolutegravir in real life setting. Poster 948 presented at CROI 2016. February 2016 [internet publication].Texto completo
37. Torok ME, Kambugu A, Wright E. Immune reconstitution disease of the central nervous system. Curr Opin HIV AIDS. 2008 Jul;3(4):438-45. Resumo
38. Bicanic T, Meintjes G, Rebe K, et al. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):130-4. Resumo
39. McCombe JA, Auer RN, Maingat FG, et al. Neurologic immune reconstitution inflammatory syndrome in HIV/AIDS: outcome and epidemiology. Neurology. 2009 Mar 3;72(9):835-41. Resumo
40. The Mind Exchange Working Group. Assessment, diagnosis and treatment of human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND): a consensus report of the Mind Exchange Program. Clin Infect Dis. 2013 Apr;56(7):1004-17. Resumo
41. Sico JJ, Chang CC, So-Armah K, et al; Veterans Aging Cohort Study. HIV status and the risk of ischemic stroke among men. Neurology. 2015 May 12;84(19):1933-40.Texto completo Resumo
42. Hinkin CH, Castellon SA, Levine AJ, et al. Neurocognition in individuals co-infected with HIV and hepatitis C. J Addict Dis. 2008;27(2):11-7. Resumo
43. Nelson M, Powles T, Zeitlin A, et al. Thyroid dysfunction and relationship to antiretroviral therapy in HIV-positive individuals in the HAART era. J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):113-4. Resumo
44. Lortholary O, Christeff N, Casassus P, et al. Hypothalamo-pituitary-adrenal function in human immunodeficiency virus-infected men. J Clin Endocrinol Metab. 1996 Feb;81(2):791-6. Resumo
45. Mayo J, Collazos J, Martínez E, et al. Adrenal function in the human immunodeficiency virus-infected patient. Arch Intern Med. 2002 May 27;162(10):1095-8.Texto completo Resumo
46. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed, text revision. Washington, DC: American Psychiatric Press; 2022.
47. Chaudhuri A, Kennedy PG. Diagnosis and treatment of viral encephalitis. Postgrad Med J. 2002 Oct;78(924):575-83.Texto completo Resumo
48. Tang MW, Clemons KV, Katzenstein DA, et al. The cryptococcal antigen lateral flow assay: a point-of-care diagnostic at an opportune time. Crit Rev Microbiol. 2016 Aug;42(4):634-42. Resumo
49. Lavi R, Yarnitsky D, Rowe JM, et al. Standard vs atraumatic Whitacre needle for diagnostic lumbar puncture: a randomized trial. Neurology. 2006 Oct 24;67(8):1492-4. Resumo
50. Arendt K, Demaerschalk BM, Wingerchuk DM, et al. Atraumatic lumbar puncture needles: after all these years, are we still missing the point? Neurologist. 2009 Jan;15(1):17-20. Resumo
51. Nath S, Koziarz A, Badhiwala JH, et al. Atraumatic versus conventional lumbar puncture needles: a systematic review and meta-analysis. Lancet. 2018 Mar 24;391(10126):1197-204. Resumo
52. Rochwerg B, Almenawer SA, Siemieniuk RAC, et al. Atraumatic (pencil-point) versus conventional needles for lumbar puncture: a clinical practice guideline. BMJ. 2018 May 22;361:k1920.Texto completo
53. Ahmed SV, Jayawarna C, Jude E. Post lumbar puncture headache: diagnosis and management. Postgrad Med J. 2006 Nov;82(973):713-6.Texto completo Resumo
54. Arevalo-Rodriguez I, Ciapponi A, Roqué i Figuls M, et al. Posture and fluids for preventing post-dural puncture headache. Cochrane Database Syst Rev. 2016 Mar 7;(3):CD009199.Texto completo Resumo
55. Bayraktar S, Bayraktar UD, Ramos JC, et al. Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. J Neurooncol. 2011 Jan;101(2):257-65.Texto completo Resumo
56. Lurain K, Uldrick TS, Ramaswami R, et al. Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate. Blood. 2020 Nov 5;136(19):2229-32.Texto completo
57. Elliot ER, Theodoraki A, Jain LR, et al. Iatrogenic Cushing's syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies. Clin Med (Lond). 2016 Oct;16(5):412-8.Texto completo Resumo
58. Akgün KM, Krishnan S, Tate J, et al. Delirium among people aging with and without HIV: role of alcohol and neurocognitively active medications. J Am Geriatr Soc. 2023 Jun;71(6):1861-72.Texto completo Resumo
59. Tamargo JA MS, Campa A PhD, Martinez SS PhD, et al. Cognitive impairment among people who use heroin and fentanyl: findings from the Miami Adult Studies on HIV (MASH) cohort. J Psychoactive Drugs. 2021 Jul-Aug;53(3):215-23.Texto completo Resumo
60. American Psychiatric Association. HIV psychiatry. 2012 [internet publication].Texto completo
61. Benjamin LA, Bryer A, Emsley HC, et al. HIV infection and stroke: current perspectives and future directions. Lancet Neurol. 2012 Oct;11(10):878-90.Texto completo Resumo
62. Chrétien F, Bélec L, Hilton DA, et al. Herpes simplex virus type 1 encephalitis in acquired immunodeficiency syndrome. Neuropathol Appl Neurobiol. 1996 Oct;22(5):394-404. Resumo
63. Corti M, Villafañe MF, Vittar N, et al. Meningoencephalitis due to varicella zoster virus in AIDS patients. Report of eleven cases and review of the literature. Rev Inst Med Trop Sao Paulo. 2015 Dec;57(6):505-8.Texto completo Resumo
64. Narvaneni S, Tagliaferri AR, Reid RJ, et al. A case of cytomegalovirus encephalitis in cluster of differentiation four cell counts greater than 50. Cureus. 2021 Oct;13(10):e18550.Texto completo Resumo
65. Derbie A, Mekonnen D, Woldeamanuel Y, et al. Cryptococcal antigenemia and its predictors among HIV infected patients in resource limited settings: a systematic review. BMC Infect Dis. 2020 Jun 11;20(1):407.Texto completo Resumo
66. Coleman B, Smith BR, Kapoor R, et al. Persistence of human immunodeficiency virus-associated cerebral toxoplasmosis lesions in successfully treated patients receiving combination antiretroviral therapy. Open Forum Infect Dis. 2023 May;10(5):ofad208.Texto completo Resumo
67. McDermott LM, Ebmeier KP. A meta-analysis of depression severity and cognitive function. J Affect Disord. 2009 Dec;119(1-3):1-8. Resumo
68. Jiang R, Song Z, Liu L, et al. Survival and prognostic factors of progressive multifocal leukoencephalopathy in people living with HIV in modern ART era. Front Cell Infect Microbiol. 2023;13:1208155.Texto completo Resumo
69. Jung AC, Paauw DS. Diagnosing HIV-related disease: using the CD4 count as a guide. J Gen Intern Med. 1998 Feb;13(2):131-6.Texto completo Resumo
70. Jayasena CN, de Silva NL, O'Reilly MW, et al. Standardising the biochemical confirmation of adult male hypogonadism; a joint position statement by the Society for Endocrinology and Association of Clinical Biochemistry and Laboratory Medicine. Ann Clin Biochem. 2023 Jul;60(4):223-7.Texto completo Resumo
71. Tan A, Yin JD, Tan LW, et al. Using the Berlin questionnaire to predict obstructive sleep apnea in the general population. J Clin Sleep Med. 2017 Mar 15;13(3):427-32.Texto completo Resumo
72. Gingo MR, Balasubramani GK, Rice TB, et al. Pulmonary symptoms and diagnoses are associated with HIV in the MACS and WIHS cohorts. BMC Pulm Med. 2014 Apr 30;14:75.Texto completo Resumo
73. Brew BJ, Pemberton L, Cunningham P, et al. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis. 1997 Apr;175(4):963-6. Resumo
74. Soulie C, Fourati S, Lambert-Niclot S, et al. HIV genetic distance between plasma and CSF in patients with neurological disorders. Dubrovnik, Croatia: International HIV and Hepatitis Drug Resistance Workshop; June 2010.
75. Eggers C, Hertogs K, Sturenburg HJ, et al. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. AIDS. 2003 Sep 5;17(13):1897-906. Resumo
76. Letendre SL, McCutchan JA, Childers ME, et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol. 2004 Sep;56(3):416-23. Resumo
77. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008 Jan;65(1):65-70.Texto completo Resumo
78. De Luca A, Ciancio BC, Larussa D, et al. Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals. Neurology. 2002 Aug 13;59(3):342-7. Resumo
79. Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis. 2010 Mar 1;50(5):773-8. Resumo
80. British HIV Association. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update). August 2016 [internet publication].Texto completo
81. Ellis RJ, Letendre S, Vaida F, et al. Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. Clin Infect Dis. 2014 Apr;58(7):1015-22.Texto completo Resumo
82. Vidal JE. HIV-related cerebral toxoplasmosis revisited: current concepts and controversies of an old disease. J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958219867315.Texto completo Resumo
83. Czarnowska-Cubała M, Wiglusz MS, Cubała WJ, et al. MR findings in neurosyphilis--a literature review with a focus on a practical approach to neuroimaging. Psychiatr Danub. 2013 Sep;25 Suppl 2:S153-7. Resumo
84. Liu H, Dong D. MRI of neurosyphilis with mesiotemporal lobe lesions of "knife-cut sign" on MRI: a case report and literature review. Heliyon. 2023 Mar 25;9(4):e14787.Texto completo Resumo
85. Milanini B, Valcour V. Differentiating HIV-associated neurocognitive disorders from Alzheimer's disease: an emerging issue in geriatric neuroHIV. Curr HIV/AIDS Rep. 2017 Aug;14(4):123-32.Texto completo Resumo
86. Hernandez AV, de Laurentis L, Souza I, et al. Diagnostic accuracy of Xpert MTB/RIF for tuberculous meningitis: systematic review and meta-analysis. Trop Med Int Health. 2021 Feb;26(2):122-32.Texto completo Resumo
87. European AIDS Clinical Society. Guidelines: version 12.1 Nov 2024 [internet publication].Texto completo
88. Power C, Selnes OA, Grim JA, et al. HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Mar 1;8(3):273-8. Resumo
89. Morgan EE, Woods SP, Scott JC, et al. Predictive validity of demographically adjusted normative standards for the HIV Dementia Scale. J Clin Exp Neuropsychol. 2008 Jan;30(1):83-90. Resumo
90. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010 Jun 1;24(9):1243-50. Resumo
91. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. Resumo
92. Overton ET, Azad TD, Parker N, et al. The Alzheimer's disease-8 and Montreal Cognitive Assessment as screening tools for neurocognitive impairment in HIV-infected persons. J Neurovirol. 2013 Feb;19(1):109-16. Resumo
93. Brouillette MJ, Mayo N, Fellows LK, et al. A better screening tool for HIV-associated neurocognitive disorders: is it what clinicians need? AIDS. 2015 May 15;29(8):895-902.Texto completo Resumo
94. Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007 Sep 12;21(14):1915-21. Resumo
95. Carey CL, Woods SP, Rippeth JD, et al. Initial validation of a screening battery for the detection of HIV-associated cognitive impairment. Clinic Neuropsychol. 2004 May;18(2):234-48. Resumo
96. Morrison C, Mellins CA, Synder C, et al. Optimizing generalized anxiety disorder screening in young adults perinatally affected by HIV: a psychometric analysis. J Mood Anxiety Disord. 2024 Sep:7:100066.Texto completo Resumo
97. Brown RL, Rounds LA. Conjoint screening questionnaires for alcohol and other drug abuse: criterion validity in a primary care practice. Wis Med J. 1995;94(3):135-40. Resumo
98. Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017 Jan 15;64(2):111-5.Texto completo Resumo
99. Geldmacher H, Taube C, Kroeger C, et al. Assessment of lymph node tuberculosis in northern Germany: a clinical review. Chest. 2002 Apr;121(4):1177-82. Resumo
100. Weir MR, Thornton GF. Extrapulmonary tuberculosis. Experience of a community hospital and review of the literature. Am J Med. 1985 Oct;79(4):467-78. Resumo
101. Baydur A. The spectrum of extrapulmonary tuberculosis. West J Med. 1977 Apr;126(4):253-62.Texto completo Resumo
102. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection. Mar 2024 [internet publication].Texto completo
103. Bjerrum S, Schiller I, Dendukuri N, et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV. Cochrane Database Syst Rev. 2019 Oct 21;10:CD011420.Texto completo Resumo
104. Beuschlein F, Else T, Bancos I, et al. European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: diagnosis and therapy of glucocorticoid-induced adrenal insufficiency. J Clin Endocrinol Metab. 2024 Jun 17;109(7):1657-83.Texto completo Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal